Author:
Behl Supriya,Hamel Nancy,de Ladurantaye Manon,Lepage Stéphanie,Lapointe Réjean,Mes-Masson Anne-Marie,Foulkes William D.
Abstract
AbstractInherited germline pathogenic variants are responsible for ~5% of breast cancer globally. Through rapid expansion and isolation since immigration in the early 17th century, French Canadians are a relatively genetically homogenous founder population and therefore represent a unique demographic for genetic contributions to disease. To date, twenty variants in BRCA1, BRCA2, and PALB2 that predispose families to breast and ovarian cancer have been identified as recurring in the French-Canadian founder population. Our objective was to evaluate the clinical efficacy and validity of targeted genetic testing for these variants in Montreal French Canadians. A total of 555 breast cancer cases unselected for family history or age of diagnosis were genotyped, along with 1940 controls without a personal or family history of cancer. A Sequenom genotyping assay identified a pathogenic variant in 0.2% (5 of 1940) of cancer-free controls, and 3.8% (21/555) of breast cancer cases. Almost 10% (12/113) of early onset cases were heterozygous for founder BRCA1 or BRCA2 pathogenic variant. Of twenty variants tested, only seven were identified in this study. The option of providing this test as population-based screening is discussed.
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2017., (Toronto, Ontario, Canada, 2017).
2. Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4, 665–676, https://doi.org/10.1038/nrc1431 (2004).
3. Kuchenbaecker, K. B. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317, 2402–2416, https://doi.org/10.1001/jama.2017.7112 (2017).
4. Nielsen, F. C., van Overeem Hansen, T. & Sorensen, C. S. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 16, 599–612, https://doi.org/10.1038/nrc.2016.72 (2016).
5. Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371, 497–506, https://doi.org/10.1056/NEJMoa1400382 (2014).
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献